Methods of predicting resistance or sensitivity to therapies for cancer
View Patent ↗The present application is directed to methods of predicting the resistance of a tumor to molecularly targeted therapy and methods of predicting sensitivity of a tumor to DNA damaging therapy. The methods include: a) determining the level of expression of plurality of genes regulated by retinoblastoma tumor supressor (RB) in the individual, and b) comparing the level of expression of the plurality of genes regulated by RB in the individual with a level of expression of the plurality of genes regulated by RB in a control. The application is also directed to an RNA expression profile for the loss of RB.
1. A method of managing treatment of a human having an (ER)-positive human breast cancer tumor, the method comprising:
a) obtaining a sample of the tumor from the human;
b) determining an average level of expression of a plurality of genes regulated by retinoblastoma tumor suppressor (RB) in the sample by determining the average level of expressed RNA of the plurality of genes regulated by RB, wherein the plurality of genes regulated by RB consists of: RAD21, BRCA1, ECT2, KIF11, SMC4L1, TOPBP1, STK6, KIF20A, CDC25C, CCNB1, CDC20, CDCA8, KIF2G, BIRC5, CDC45L, CDCA3, PRC1, CCN82, MK167, RAD51, CDCA5, BRRN1, TTK, KIF23, BUB1, CENPA, CCNA2, RRM2, TRIP13, EZH2, MAD2L1, TOP2A, RAD51AP1, TYMS, PCNA, HMGB2, FEN1, NEK2, CKS2, CHEK1, CDC6, GMNN, FIGNL1, TMPO, TCF19, LIG1, MCM2, MCM3, BRCA2, SMC2L1, PRIM1, RFC5, CDK2, CDCA7, PLTP, and TYRO3;
c) determining whether the tumor is resistant to antiestrogen therapy by comparing the average level of expression of the plurality of genes regulated by RB in the sample with an average level of expression of the plurality of genes regulated by RB in a control, wherein the control represents a tumor responsive or non-responsive to the antiestrogen therapy, and wherein the antiestrogen therapy comprises tamoxifen; and
d) managing the treatment of the human by (i) treating the human with antiestrogen therapy as a first-line therapy where the tumor is not resistant to the antiestrogen therapy, and (ii) treating the human with DNA-damaging therapy as a first-line therapy where the tumor is resistant to the antiestrogen therapy.
2. The method of claim 1 , wherein the average level of expressed RNA is determined by microarray analysis, quantitative polymerase chain reaction, or a combination thereof.
3. The method of claim 1 , wherein the tumor is resistant to antiestrogen therapy when:
the sample has an average higher expression of the plurality of genes regulated by RB as compared with a control representing a tumor responsive to the antiestrogen therapy, and
the sample has an average similar level of expression of the plurality of genes regulated by RB as compared with a control representing a tumor resistant to the antiestrogen therapy.
4. The method of claim 3 , wherein the higher expression is at least about 2 fold higher in the sample as compared with the control.
5. The method of claim 3 , wherein the average higher expression of the plurality of genes regulated by RB is from about 1.5 to 2.0 normalized intensity.
6. The method of claim 1 , wherein the treating with antiestrogen therapy comprises treating with tamoxifen.
7. The method of claim 1 , wherein the DNA-damaging therapy comprises radiation or chemotherapy.
8. The method of claim 1 , wherein a human having a sample with an average higher expression of the plurality of genes regulated by RB as compared with a control representing a tumor responsive to the antiestrogen therapy indicates that the human will have an increased incidence of cancer recurrence relative to a human having a sample with an average low or average medium expression of the plurality of genes regulated by RB as compared with a control representing a tumor responsive to the antiestrogen therapy.
9. The method of claim 8 , wherein the increased incidence of cancer recurrence is about 65%.